Literature DB >> 9596497

Malignant epithelial tumors of the lacrimal gland: a clinicopathologic study of 21 cases.

R L Font1, S L Smith, R G Bryan.   

Abstract

OBJECTIVE: To analyze 120 lacrimal gland masses collected during a 23-year period in the Ophthalmic Pathology Laboratory at the Cullen Eye Institute, Houston, Tex.
METHODS: Of the 120 lacrimal gland tumors, we focused on a detailed clinicopathologic study of 21 malignant epithelial tumors. Follow-up was available in 19 (90%) of 21 cases.
RESULTS: About two thirds of the masses (75 cases) were inflammatory, one third (41 cases) were of epithelial origin, and 3% (4 cases) were malignant lymphomas. Of the epithelial tumors, 17 (41%) were benign mixed tumors, 12 (29%) were adenoid cystic carcinomas arising de novo, 2 (5%) were adenocarcinoma arising de novo, 7 (17%) were malignant mixed tumors, and 3 (7%) were metastatic carcinoma. All of the patients with adenoid cystic carcinoma had local recurrences, and 60% of the patients died of their tumors (mean survival, 5 years); only 2 patients were alive 13 and 16 years after the initial surgery, both of whom had radical surgical procedures for recurrence following orbital exenteration.
CONCLUSION: The histopathologic classification and management of these tumors are discussed. This study supports the dismal prognosis of adenoid cystic carcinoma arising de novo.

Entities:  

Mesh:

Year:  1998        PMID: 9596497     DOI: 10.1001/archopht.116.5.613

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  36 in total

1.  Adenoid cystic carcinoma of the lacrimal gland is frequently characterized by MYB rearrangement.

Authors:  T Y Chen; M G Keeney; A V Chintakuntlawar; D L Knutson; S Kloft-Nelson; P T Greipp; J A Garrity; D R Salomao; J J Garcia
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

2.  [Diseases of the lacrimal gland].

Authors:  N Fichter; M Schittkowski; R F Guthoff
Journal:  Ophthalmologe       Date:  2005-04       Impact factor: 1.059

3.  Skull base invasion of adenoid cystic carcinoma of the lacrimal gland : a case report.

Authors:  Jae Il Lee; Young Zoon Kim; Eun Hee Lee; Kyu Hong Kim
Journal:  J Korean Neurosurg Soc       Date:  2008-10-30

4.  A rare case of late solitary vertebral metastasis from an adenoid cystic carcinoma of the lacrimal gland.

Authors:  Awaiz Ahmed; Satish Kannan Rajankulam Ganesan; Shahnawaz Haleem; James Nicoll
Journal:  BMJ Case Rep       Date:  2017-06-13

5.  Accuracy of fine needle aspiration biopsy processed by cytologic smear and cell block techniques for the diagnosis of lacrimal gland tumors: a study of 48 cases.

Authors:  Xiangning Wang; Jiang Qian; Yifei Yuan; Bo Ping; Liqing Feng; Yingwen Bi; Xiaping Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

6.  Usefulness of colour Doppler flow imaging in the management of lacrimal gland lesions.

Authors:  A Lecler; M Boucenna; F Lafitte; P Koskas; E Nau; P V Jacomet; O Galatoire; S Morax; M Putterman; F Mann; F Héran; J C Sadik; H Picard; O Bergès
Journal:  Eur Radiol       Date:  2016-06-07       Impact factor: 5.315

7.  A 68-year-old man with a recurrent orbital lesion.

Authors:  Marc-Andre Rheaume; Guy Allaire; Akram Rahal; Vijayabalan Balasingam; Patrick R Boulos
Journal:  Digit J Ophthalmol       Date:  2009-09-02

8.  Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma.

Authors:  David T Tse
Journal:  Trans Am Ophthalmol Soc       Date:  2005

9.  Long-term outcomes of neoadjuvant intra-arterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma.

Authors:  David T Tse; Andrea L Kossler; William J Feuer; Pasquale W Benedetto
Journal:  Ophthalmology       Date:  2013-04-09       Impact factor: 12.079

Review 10.  Carcinosarcoma of the orbit: report of two cases and review of the literature.

Authors:  Sasapin G Prakalapakorn; C Robert Bernardino; Paul L Auclair; Hans E Grossniklaus
Journal:  Ophthalmology       Date:  2008-06-17       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.